Figure 3A illustrates the ROR for the top 40 psychiatric AEs in the FAERS database under various GLP-1 RA treatments
doi:10.1016/S2213-8587(22)00070-5 202
The pellet was resuspended in PBS to obtain a bacterial culture of OD 600 40
D3, K2, B12, magnesium glycinate and ginger, each at a dose that earns its place
The primary mechanisms of action include: Enhanced insulin secretion : GLP-1 receptor agonists stimulate glucose-dependent insulin release from pancreatic beta cells, improving glycaemic control without causing hypoglycaemia when glucose levels are normal Suppressed glucagon secretion : These agents inhibit inappropriate glucagon release from pancreatic alpha cells, reducing hepatic glucose production Delayed gastric emptying : By slowing the rate at which food leaves the stomach, GLP-1 medications prolong satiety and reduce postprandial glucose excursions Central appetite regulation : GLP-1 receptors in the hypothalamus and brainstem mediate reduced appetite and food intake, leading to decreased caloric consumption Regarding visceral fat specifically, some imaging substudies suggest GLP-1 receptor agonists may reduce visceral adipose tissue alongside subcutaneous fat
Here are the technicalities of it: In the study illustrated on the right*, for GSH, no more Glutathione could be detected in the blood after approximately 10 minutes
